Enhanced Phosphorothioate-conjugated miRNAs for Improved Disease Treatment

The inventive concept enhances phosphorothioate-conjugated miRNAs for treating multiple myeloma and inhibiting IL-6 signaling by introducing improved stability, potency, and bioavailability through modified phosphorothioate linkers.

The original patent disclosed phosphorothioate-conjugated miRNAs for disease treatment, but limitations included reduced cellular uptake, off-target effects, and varying potency. The new inventive concept addresses these limitations by incorporating optimized phosphorothioate linkers, resulting in improved treatment outcomes.

The enhanced phosphorothioate-conjugated miRNAs comprise a microRNA selected from let7a-3p, let7a-5p, miR17-3p, miR17-5p, and miR218-5p, and a phosphorothioate linker modified to improve stability, potency, and bioavailability. The linker modifications enable increased cellular uptake, reduced off-target effects, and enhanced therapeutic efficacy. The inventive concept can be applied to various disease treatments, including multiple myeloma and IL-6 signaling inhibition.

The new claims introduce novel phosphorothioate linker modifications, which provide improved stability, potency, and bioavailability compared to the original patent. These modifications constitute an inventive step, as they address specific limitations of the original patent and provide a significant improvement in treatment outcomes.

Alternative embodiments may include varying the microRNA selection, linker modification strategies, or conjugation methods to further optimize the inventive concept. Variations could also involve combining the enhanced phosphorothioate-conjugated miRNAs with other therapeutic agents or delivery systems.

The enhanced phosphorothioate-conjugated miRNAs have significant commercial potential in the treatment of multiple myeloma and other diseases, with potential applications in the biotechnology and pharmaceutical industries. The target market includes hospitals, research institutions, and biotech companies focused on disease treatment and gene therapy.